Expanded access programmes: patient interests versus clinical trial integrity

Affiliations

• ¹ University of Manchester/The Christie NHS Foundation Trust, Manchester, UK. Electronic address: paul.lorigan@christie.nhs.uk.
• ² Istituto Nazionale Tumori Fondazione Pascale, Naples, Italy.
• ³ University of Zurich, Zurich, Switzerland.
• ⁴ Gustave Roussy Cancer Campus, Villejuif Grand, Paris, France.
• ⁵ Massachusetts General Hospital, Boston, MA, USA.
• ⁶ University Medical Center Tübingen, Tübingen, Germany.
• ⁷ Department of Medicine, University of Athens, Athens, Greece.
• ⁸ University Hospital Schleswig-Holstein, Campus Kiel, Kiel, Germany.
• ⁹ Melanoma Institute Australia, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia; Macquarie University, Sydney, NSW, Australia.
• ¹⁰ Melanoma Program, University of Pittsburgh Cancer Institute, Pittsburgh, PA, USA.
• ¹¹ Royal Marsden Hospital NHS Foundation Trust, London, UK.
• ¹² Melanoma Institute Australia, Sydney, NSW, Australia; University of Sydney, Sydney, NSW, Australia.
• ¹³ University Hospital of Siena, Siena, Italy.
• ¹⁴ Peter MacCallum Cancer Centre, East Melbourne, and University of Melbourne, Parkville, VIC, Australia.
• ¹⁵ University of California, Los Angeles, CA, USA.
• ¹⁶ Gustave Roussy Cancer Campus, Villejuif Grand, Paris, France; INSERM U981, Villejuif-Paris-Sud, France.
• ¹⁷ University Hospital Essen, Essen, Germany.
• ¹⁸ H Lee Moffitt Cancer Center, Tampa, FL, USA.
• ¹⁹ Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
• ²⁰ University of Manchester/The Christie NHS Foundation Trust, Manchester, UK.